EKSO
$10.78
Ekso Bionics Holdings, Inc.
Recent News
Integra LifeSciences (IART) Beats Q4 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of +4.73% and +0.13%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
How The Ekso Bionics Holdings Narrative Is Shifting After Q3 And A Higher Price Target
Why Ekso Bionics’ Price Target Just Moved Ekso Bionics Holdings just saw its price target reset to US$6, a level that bullish analysts link to the Q3 update and a view that the company is executing more in line with its current plan. Supporters highlight the Q3 sales recovery and the ongoing business review as reasons to keep the fair value anchor unchanged while expressing more confidence in how the story could unfold, whereas more cautious voices stress that one quarter and an open ended...
How The New Price Target Is Shaping Ekso Bionics Holdings (EKSO) Story
What the New Price Target Means for Ekso Bionics Holdings Ekso Bionics Holdings is back in focus after a change in the stock's price target, putting fresh attention on how the market is currently framing its story. With no prior target to compare against, this new level acts as a reference point for how analysts are thinking about the company right now. Stay tuned to see how you can keep track of future price target updates and shifts in the Ekso Bionics narrative as they emerge. Analyst...
How Recent Developments Are Rewriting The Story For Ekso Bionics Holdings (EKSO)
Ekso Bionics Holdings has just seen its fair value estimate lifted from US$7.75 to US$9.50, with only a small adjustment to the discount rate to about 8.10% and core assumptions such as revenue growth of about 25.34% left effectively unchanged. This shift reflects how recent Q3 results and the ongoing review of the current business are reshaping analyst confidence around what the current setup might support, even as opinions remain split on how durable the recent sales recovery will be...